Shares of Kenvue Inc. (NYSE: KVUE) experienced a important decline on ⁣Friday, dropping‌ over 10%,‍ following​ the filing ⁤of multiple lawsuits ⁣alleging a link between over-the-counter (OTC) pain relievers, including those under the Tylenol brand, and cancer.⁣ The lawsuits claim that benzene, a known carcinogen, was found in some batches of these products.

The lawsuits, filed in various state courts, target ⁤Kenvue and Johnson & Johnson​ (J&J), from whom Kenvue was ‌spun off in may 2023. Plaintiffs allege that the companies knew or should have known about ⁣the potential for‌ benzene contamination and failed to adequately warn consumers. Benzene is a chemical used in industrial ⁣processes and can contaminate medications if not properly controlled⁣ during manufacturing.

What are⁣ the Allegations?

The ⁢core⁤ of the⁣ lawsuits centers around the presence of benzene in several Kenvue OTC products, including Tylenol, Motrin, and Benadryl. Benzene exposure has been linked to leukemia and ‌other blood cancers. The plaintiffs claim that Kenvue and ⁣J&J failed to implement sufficient quality ‌control measures to prevent benzene contamination and did not provide adequate warnings⁤ on product​ labels.

According to court documents, ‌independent testing revealed⁢ unacceptable levels of ⁢benzene in some batches of these medications. The lawsuits further allege that the companies prioritized profits over consumer safety by continuing to ​sell products with known contamination risks.

Kenvue⁣ and Johnson & Johnson’s Response

Kenvue has ⁢stated that it is aware of the lawsuits and is committed to⁣ defending it’s products. ​ In a statement released on Friday, the company said that its products meet​ all applicable safety and quality standards. Kenvue ⁢also emphasized that the levels of benzene found in the affected ‍batches were within acceptable limits set by the Food and Drug Administration (FDA).

reuters reports that Johnson & Johnson, while no longer directly responsible for the manufacturing of these products, faces liability due to its ancient involvement and the‍ spin-off ‌of Kenvue. J&J ⁣has not yet issued a complete public statement regarding the lawsuits, but is ​expected⁢ to cooperate with Kenvue’s defence.

FDA Involvement and Regulatory Context

The Food and Drug Administration (FDA) has been monitoring benzene levels in OTC medications since 2019, following reports of contamination⁤ in hand sanitizers.​ The FDA has established⁣ a guidance level⁣ of 2 parts per million⁣ (ppm) for benzene in OTC drug products. While⁣ some batches of Kenvue products reportedly exceeded this